Identification

Name
Silodosin
Accession Number
DB06207
Type
Small Molecule
Groups
Approved
Description

Silodosin is an α1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. FDA approved Oct 9, 2008.

Structure
Thumb
Synonyms
  • KAD 3213
  • KMD 3213
  • Urief
External IDs
KAD-3213 / KMD-3213
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RapafloCapsule8 mgOralAllergan Pharma Co.2011-10-26Not applicableCanada
RapafloCapsule4 mg/1OralActavis Pharma Company2009-03-23Not applicableUs52544 0151 30 nlmimage10 343e9a24
RapafloCapsule8 mg/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs
RapafloCapsule4 mg/1OralAllergan2009-03-23Not applicableUs
RapafloCapsule4 mgOralAllergan Pharma Co.2011-10-26Not applicableCanada
RapafloCapsule4 mg/1OralAvera Mc Kennan Hospital2015-05-01Not applicableUs
RapafloCapsule8 mg/1OralActavis Pharma Company2009-03-23Not applicableUs52544 0152 30 nlmimage10 041c8214
RapafloCapsule8 mg/1OralAllergan2009-03-23Not applicableUs
RapafloCapsule8 mg/1OralAvera Mc Kennan Hospital2015-03-23Not applicableUs
SilodyxCapsule8 mgOralRecordati Ireland Ltd2010-01-29Not applicableEu
International/Other Brands
Rapaflo / Rapilif (Ipca Urosciences ) / Silodyx (Recordati Industria Chimica e Farmaceutica S.p.A.) / Urief (Watson Pharmaceuticals Inc.)
Categories
UNII
CUZ39LUY82
CAS number
160970-54-7
Weight
Average: 495.5345
Monoisotopic: 495.234491142
Chemical Formula
C25H32F3N3O4
InChI Key
PNCPYILNMDWPEY-QGZVFWFLSA-N
InChI
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
IUPAC Name
1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide
SMILES
C[[email protected]](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F

Pharmacology

Indication

Treatment for symptomatic relief of benign prostatic hyperplasia

Structured Indications
Pharmacodynamics

Silodosin is 583 times more selective for human alpha-1A receptors than alpha-1B receptors. It is also 56 times more selective for human alpha-1A receptors than alpha-1D. Silodosin does not prolong the QT interval.

Mechanism of action

Benign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
Absorption

Quickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose). When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: Cmax = 61.6 ± 27.54 ng/mL; Tmax = 2.6 ± 0.90 hours;
AUC (0h-24h) = 373 ng•hr/ml. The AUC of its metabolite, KMD3213G, is four times greater than silodosin.

Volume of distribution

49.5 L

Protein binding

97% bound to protein

Metabolism

Extensively metabolized in the liver. The main metabolite is generated via glucuronidation (KMD-3213G) by UDP-2B7. Oxidation by alcohol and aldehyde dehydrogenases produces the second major metabolite, KMD-3293. KMD-3213G accumulates in the plasma as it is very hydrophilic. KMD-3213G is also an active metabolite in which it has 50% of silodosin's inhibitory activity. KMD-3293 is inactive. Cytochrome P450 CYP 3A4 also generates some metabolites.

Route of elimination

Fecal (54.9%);
Renal (33.5%)

Half life

Silodosin = 13.3 ± 8.07 hours; KMD-3213G = 24 hours;

Clearance

Plasma clearance = 10 L/h

Toxicity

Most common adverse reactions (incidence > 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbemaciclibThe serum concentration of Silodosin can be increased when it is combined with Abemaciclib.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
AcetaminophenThe serum concentration of Silodosin can be increased when it is combined with Acetaminophen.Approved
AdrafinilSilodosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Silodosin can be increased when it is combined with Afatinib.Approved
AgmatineThe risk or severity of hypotension can be increased when Silodosin is combined with Agmatine.Experimental, Investigational
AlbendazoleThe serum concentration of Silodosin can be increased when it is combined with Albendazole.Approved, Vet Approved
AlectinibThe serum concentration of Silodosin can be increased when it is combined with Alectinib.Approved, Investigational
AlfentanilThe serum concentration of Silodosin can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Silodosin.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Withdrawn
AmantadineThe serum concentration of Silodosin can be increased when it is combined with Amantadine.Approved
AmibegronSilodosin may decrease the vasoconstricting activities of Amibegron.Investigational
Aminohippuric acidThe serum concentration of Silodosin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitrazSilodosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineThe serum concentration of Silodosin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Silodosin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Silodosin can be increased when it is combined with Amprenavir.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Silodosin is combined with Amrinone.Approved
AmsacrineThe serum concentration of Silodosin can be increased when it is combined with Amsacrine.Approved, Investigational
AnisodamineSilodosin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Silodosin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApraclonidineSilodosin may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Silodosin can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Aranidipine.Approved, Investigational
ArbutamineSilodosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolSilodosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Silodosin.Investigational
AstemizoleThe serum concentration of Silodosin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Silodosin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Silodosin can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Silodosin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Silodosin can be increased when it is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the hypotensive activities of Silodosin.Approved
AzelastineThe serum concentration of Silodosin can be increased when it is combined with Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Silodosin is combined with Azimilide.Investigational
AzithromycinThe serum concentration of Silodosin can be increased when it is combined with Azithromycin.Approved
BarnidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Silodosin.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Silodosin is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Benidipine.Approved, Investigational
BenzocaineThe serum concentration of Silodosin can be increased when it is combined with Benzocaine.Approved, Investigational
BepridilThe serum concentration of Silodosin can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
BevantololBevantolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BiperidenThe serum concentration of Silodosin can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BitolterolSilodosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of Silodosin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BortezomibThe metabolism of Silodosin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Silodosin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Silodosin can be increased when it is combined with Bosutinib.Approved
BrimonidineSilodosin may decrease the vasoconstricting activities of Brimonidine.Approved
BromocriptineThe serum concentration of Silodosin can be increased when it is combined with Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the orthostatic hypotensive activities of Silodosin.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Silodosin.Experimental, Investigational
BunazosinSilodosin may increase the antihypertensive activities of Bunazosin.Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Silodosin.Approved
BuprenorphineThe serum concentration of Silodosin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Silodosin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Silodosin can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Silodosin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Silodosin can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Silodosin can be increased when it is combined with Candesartan.Experimental
Candesartan cilexetilThe serum concentration of Silodosin can be increased when it is combined with Candesartan cilexetil.Approved
CaptoprilThe serum concentration of Silodosin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Silodosin can be increased when it is combined with Carbamazepine.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Silodosin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Silodosin is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Silodosin.Approved
CarvedilolThe serum concentration of Silodosin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Silodosin can be increased when it is combined with Caspofungin.Approved
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
CeritinibThe serum concentration of Silodosin can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Silodosin can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorpromazineThe serum concentration of Silodosin can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe serum concentration of Silodosin can be increased when it is combined with Chlorpropamide.Approved, Investigational
ChlorprothixeneThe serum concentration of Silodosin can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholesterolThe serum concentration of Silodosin can be increased when it is combined with Cholesterol.Approved, Experimental, Investigational
CilazaprilThe serum concentration of Silodosin can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Silodosin can be increased when it is combined with Cimetidine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Silodosin is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe serum concentration of Silodosin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CirazolineSilodosin may decrease the vasoconstricting activities of Cirazoline.Experimental
CitalopramThe serum concentration of Silodosin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Silodosin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Silodosin can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolSilodosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Clevidipine.Approved, Investigational
ClofazimineThe serum concentration of Silodosin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Silodosin can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineSilodosin may decrease the vasoconstricting activities of Clonidine.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Silodosin.Experimental
ClotrimazoleThe serum concentration of Silodosin can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Silodosin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Silodosin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Silodosin can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Silodosin.Approved, Investigational
CrizotinibThe serum concentration of Silodosin can be increased when it is combined with Crizotinib.Approved
CyclandelateThe risk or severity of hypotension can be increased when Silodosin is combined with Cyclandelate.Approved
CyclophosphamideThe serum concentration of Silodosin can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Silodosin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Silodosin can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Silodosin can be increased when it is combined with Dactinomycin.Approved, Investigational
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Silodosin.Investigational
DarodipineThe risk or severity of hypotension can be increased when Silodosin is combined with Darodipine.Experimental
DarunavirThe serum concentration of Silodosin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Silodosin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Silodosin can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Silodosin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Silodosin can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Silodosin can be increased when it is combined with Desipramine.Approved, Investigational
DesloratadineThe serum concentration of Silodosin can be increased when it is combined with Desloratadine.Approved, Investigational
DetomidineSilodosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexamethasoneThe serum concentration of Silodosin can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineSilodosin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe serum concentration of Silodosin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Silodosin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigoxinThe serum concentration of Silodosin can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Silodosin can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe serum concentration of Silodosin can be increased when it is combined with Diltiazem.Approved, Investigational
DipivefrinSilodosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Silodosin can be increased when it is combined with Dipyridamole.Approved
DobutamineSilodosin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineSilodosin may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DotarizineThe risk or severity of hypotension can be increased when Silodosin is combined with Dotarizine.Investigational
DoxazosinThe serum concentration of Silodosin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Silodosin can be increased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Silodosin can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Silodosin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Silodosin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Silodosin can be increased when it is combined with Dronedarone.Approved
DroxidopaSilodosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Efonidipine.Approved, Investigational
EnalaprilThe serum concentration of Silodosin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Silodosin can be increased when it is combined with Enasidenib.Approved, Investigational
EnzalutamideThe serum concentration of Silodosin can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Silodosin.Experimental
EperisoneThe risk or severity of hypotension can be increased when Silodosin is combined with Eperisone.Approved, Investigational
EphedrineSilodosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineSilodosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineSilodosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
ErgonovineThe serum concentration of Silodosin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Silodosin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Silodosin can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Silodosin.Approved
EstramustineThe serum concentration of Silodosin can be increased when it is combined with Estramustine.Approved, Investigational
EthosuximideThe risk or severity of hypotension can be increased when Silodosin is combined with Ethosuximide.Approved
EtilefrineSilodosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtoposideThe serum concentration of Silodosin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Silodosin can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Silodosin can be increased when it is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Silodosin is combined with Fendiline.Withdrawn
FenoterolSilodosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe serum concentration of Silodosin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Silodosin can be increased when it is combined with Fexofenadine.Approved, Investigational
FidaxomicinThe serum concentration of Silodosin can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Silodosin can be increased when it is combined with Fluconazole.Approved, Investigational
FlunarizineThe risk or severity of hypotension can be increased when Silodosin is combined with Flunarizine.Approved
FluoxetineThe serum concentration of Silodosin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Silodosin can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Silodosin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Silodosin can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Silodosin is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe serum concentration of Silodosin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolSilodosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Silodosin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Silodosin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Silodosin can be increased when combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Silodosin can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Silodosin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Silodosin is combined with Gallopamil.Investigational
GefitinibThe serum concentration of Silodosin can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Silodosin can be increased when it is combined with Genistein.Investigational
GlecaprevirThe serum concentration of Silodosin can be increased when it is combined with Glecaprevir.Approved, Investigational
GlyburideThe serum concentration of Silodosin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Silodosin can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Silodosin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Silodosin can be increased when it is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuanabenzSilodosin may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineSilodosin may decrease the vasoconstricting activities of Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Silodosin can be increased when it is combined with Haloperidol.Approved
HexoprenalineSilodosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineSilodosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydrocortisoneThe serum concentration of Silodosin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Silodosin can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Silodosin can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Silodosin can be increased when it is combined with Imipramine.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Silodosin.Withdrawn
IndinavirThe serum concentration of Silodosin can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Silodosin can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminSilodosin may increase the antihypertensive activities of Indoramin.Withdrawn
IsavuconazoniumThe serum concentration of Silodosin can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoetarineSilodosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsoprenalineSilodosin may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineSilodosin may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Silodosin can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Silodosin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Silodosin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Silodosin can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
KetamineThe serum concentration of Silodosin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Silodosin can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the orthostatic hypotensive activities of Silodosin.Approved
LacidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Silodosin is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Silodosin.Investigational
LansoprazoleThe serum concentration of Silodosin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Silodosin can be increased when it is combined with Lapatinib.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Silodosin can be increased when it is combined with Letermovir.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Silodosin is combined with Levetiracetam.Approved, Investigational
LevofloxacinThe serum concentration of Silodosin can be increased when it is combined with Levofloxacin.Approved, Investigational
LidocaineThe serum concentration of Silodosin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Silodosin is combined with Lidoflazine.Experimental
LofexidineSilodosin may decrease the vasoconstricting activities of Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Silodosin can be increased when it is combined with Lomitapide.Approved, Investigational
LoperamideThe serum concentration of Silodosin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Silodosin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Silodosin can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Silodosin can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Silodosin can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Silodosin can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Silodosin can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Silodosin can be decreased when it is combined with Lumacaftor.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Silodosin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe risk or severity of hypotension can be increased when Silodosin is combined with Manidipine.Approved, Investigational
MaprotilineThe serum concentration of Silodosin can be increased when it is combined with Maprotiline.Approved, Investigational
MebendazoleThe serum concentration of Silodosin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MedetomidineSilodosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MefloquineThe serum concentration of Silodosin can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Silodosin can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MephentermineSilodosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Silodosin.Experimental
MeprobamateThe serum concentration of Silodosin can be increased when it is combined with Meprobamate.Approved, Illicit
MetaraminolSilodosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethadoneThe serum concentration of Silodosin can be increased when it is combined with Methadone.Approved
MethoxamineSilodosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineSilodosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Silodosin is combined with Methsuximide.Approved
MethyldopaSilodosin may decrease the vasoconstricting activities of Methyldopa.Approved
MetoprololThe serum concentration of Silodosin can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Silodosin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Silodosin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Silodosin can be increased when it is combined with Midazolam.Approved, Illicit
MidodrineSilodosin may decrease the vasoconstricting activities of Midodrine.Approved
MifepristoneThe serum concentration of Silodosin can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronSilodosin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Silodosin.Investigational
MitomycinThe serum concentration of Silodosin can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Silodosin can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Silodosin can be increased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Silodosin can be increased when it is combined with Morphine.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Silodosin.Approved
NaftopidilThe risk or severity of hypotension can be increased when Silodosin is combined with Naftopidil.Investigational
NaltrexoneThe serum concentration of Silodosin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineSilodosin may decrease the vasoconstricting activities of Naphazoline.Approved
NaringeninThe serum concentration of Silodosin can be increased when it is combined with Naringenin.Experimental
NebivololNebivolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
NefazodoneThe serum concentration of Silodosin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Silodosin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Silodosin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Silodosin can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Silodosin can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Silodosin can be increased when it is combined with Nicardipine.Approved, Investigational
NifedipineThe serum concentration of Silodosin can be increased when it is combined with Nifedipine.Approved
NiguldipineThe risk or severity of hypotension can be increased when Silodosin is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Silodosin can be increased when it is combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Silodosin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Silodosin is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Silodosin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Silodosin is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Silodosin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Silodosin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Silodosin can be increased when it is combined with Nitrendipine.Approved, Investigational
NorepinephrineSilodosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineSilodosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinSilodosin may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineSilodosin may decrease the vasoconstricting activities of Octopamine.Experimental
OlaparibThe metabolism of Silodosin can be decreased when combined with Olaparib.Approved
OlodaterolSilodosin may decrease the vasoconstricting activities of Olodaterol.Approved
OmeprazoleThe serum concentration of Silodosin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OrciprenalineSilodosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OsimertinibThe serum concentration of Silodosin can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Silodosin is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Silodosin.Approved
OxyfedrineSilodosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineSilodosin may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
P-NitrophenolThe serum concentration of Silodosin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Silodosin can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Silodosin can be increased when it is combined with Palbociclib.Approved, Investigational
Palmitic AcidThe serum concentration of Silodosin can be increased when it is combined with Palmitic Acid.Approved, Experimental
PantoprazoleThe serum concentration of Silodosin can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Silodosin can be increased when it is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
PentobarbitalThe metabolism of Silodosin can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerindoprilThe serum concentration of Silodosin can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe metabolism of Silodosin can be increased when combined with Phenobarbital.Approved, Investigational
PhenylephrineSilodosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineSilodosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Silodosin can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Silodosin can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimozideThe serum concentration of Silodosin can be increased when it is combined with Pimozide.Approved
PinaveriumThe risk or severity of hypotension can be increased when Silodosin is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Silodosin.Approved, Investigational
PirbuterolSilodosin may decrease the vasoconstricting activities of Pirbuterol.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Silodosin.Experimental
PonatinibThe serum concentration of Silodosin can be increased when it is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Silodosin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Silodosin.Approved
PravastatinThe serum concentration of Silodosin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Silodosin can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Silodosin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrenalterolSilodosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Silodosin is combined with Prenylamine.Withdrawn
PrimidoneThe metabolism of Silodosin can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Silodosin can be increased when it is combined with Probenecid.Approved, Investigational
ProcaterolSilodosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProgesteroneThe serum concentration of Silodosin can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Silodosin can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Silodosin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Silodosin can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Silodosin can be increased when it is combined with Protriptyline.Approved
PseudoephedrineSilodosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuercetinThe serum concentration of Silodosin can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Silodosin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Silodosin can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Silodosin can be increased when it is combined with Quinine.Approved
RacepinephrineSilodosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineSilodosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RanitidineThe serum concentration of Silodosin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Silodosin can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Silodosin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Silodosin can be increased when it is combined with Regorafenib.Approved
ReproterolSilodosin may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe serum concentration of Silodosin can be increased when it is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Silodosin can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Silodosin can be increased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Silodosin can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineSilodosin may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Silodosin can be increased when it is combined with Rilpivirine.Approved
RimiterolSilodosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RitobegronSilodosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineSilodosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Silodosin can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Silodosin can be increased when it is combined with Rolapitant.Approved, Investigational
RomifidineSilodosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RucaparibThe serum concentration of Silodosin can be increased when it is combined with Rucaparib.Approved, Investigational
SalbutamolSilodosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolSilodosin may decrease the vasoconstricting activities of Salmeterol.Approved
SaquinavirThe serum concentration of Silodosin can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Silodosin can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe serum concentration of Silodosin can be increased when it is combined with Scopolamine.Approved, Investigational
SelegilineThe serum concentration of Silodosin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Silodosin is combined with Seletracetam.Investigational
SertralineThe serum concentration of Silodosin can be increased when it is combined with Sertraline.Approved
SildenafilSildenafil may increase the hypotensive activities of Silodosin.Approved, Investigational
SiltuximabThe serum concentration of Silodosin can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Silodosin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Silodosin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Silodosin can be increased when it is combined with Sirolimus.Approved, Investigational
SolabegronSilodosin may decrease the vasoconstricting activities of Solabegron.Investigational
SorafenibThe serum concentration of Silodosin can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Silodosin.Approved
SpironolactoneThe serum concentration of Silodosin can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Silodosin can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Silodosin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Silodosin can be increased when it is combined with Stiripentol.Approved
SulfinpyrazoneThe serum concentration of Silodosin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Silodosin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Silodosin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Silodosin can be increased when it is combined with Sunitinib.Approved, Investigational
SynephrineSilodosin may decrease the vasoconstricting activities of Synephrine.Experimental
TacrineThe serum concentration of Silodosin can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Silodosin can be increased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the hypotensive activities of Silodosin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Silodosin.Investigational
TamoxifenThe serum concentration of Silodosin can be increased when it is combined with Tamoxifen.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Silodosin.Approved, Investigational
Taurocholic AcidThe serum concentration of Silodosin can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Silodosin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Silodosin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Silodosin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Silodosin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Silodosin can be increased when it is combined with Terazosin.Approved
TerbutalineSilodosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerfenadineThe serum concentration of Silodosin can be increased when it is combined with Terfenadine.Approved, Withdrawn
TerodilineThe risk or severity of hypotension can be increased when Silodosin is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Silodosin.Experimental
TestosteroneThe serum concentration of Silodosin can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Silodosin can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Silodosin can be increased when it is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe serum concentration of Silodosin can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetrahydropalmatineThe risk or severity of hypotension can be increased when Silodosin is combined with Tetrahydropalmatine.Investigational
TicagrelorThe serum concentration of Silodosin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Silodosin can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the orthostatic hypotensive activities of Silodosin.Approved
TizanidineSilodosin may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of hypotension can be increased when Silodosin is combined with Tolfenamic Acid.Approved, Investigational
TolvaptanThe serum concentration of Silodosin can be increased when it is combined with Tolvaptan.Approved
TranilastThe risk or severity of hypotension can be increased when Silodosin is combined with Tranilast.Approved, Investigational
TretoquinolSilodosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TrifluoperazineThe serum concentration of Silodosin can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Silodosin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinSilodosin may increase the antihypertensive activities of Trimazosin.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Silodosin is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Silodosin is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Silodosin can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Silodosin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Silodosin can be increased when it is combined with Troleandomycin.Approved
TulobuterolSilodosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Silodosin.Approved, Investigational
UrapidilSilodosin may increase the antihypertensive activities of Urapidil.Investigational
VardenafilVardenafil may increase the hypotensive activities of Silodosin.Approved
VelpatasvirThe serum concentration of Silodosin can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Silodosin can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Silodosin can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Silodosin can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Silodosin can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Silodosin can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Silodosin can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Silodosin is combined with Vinpocetine.Investigational
VoriconazoleThe serum concentration of Silodosin can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Silodosin can be increased when it is combined with Voxilaprevir.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Silodosin is combined with WIN 55212-2.Experimental
XamoterolSilodosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineSilodosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineThe risk or severity of hypotension can be increased when Silodosin is combined with Xylometazoline.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Silodosin is combined with Ziconotide.Approved
ZimelidineThe serum concentration of Silodosin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Silodosin can be decreased when combined with Ziprasidone.Approved
ZonisamideThe risk or severity of hypotension can be increased when Silodosin is combined with Zonisamide.Approved, Investigational
Food Interactions
  • The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin Cmax by approximately 18 − 43% and AUC by 4 − 49%

References

General References
  1. Yoshida M, Homma Y, Kawabe K: Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007 Dec;16(12):1955-65. [PubMed:18042003]
  2. Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K: Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull. 2007 Jul;30(7):1237-41. [PubMed:17603160]
External Links
KEGG Drug
D01965
PubChem Compound
5312125
PubChem Substance
175427058
ChemSpider
4471557
BindingDB
50160154
ChEBI
135929
ChEMBL
CHEMBL24778
PharmGKB
PA165291889
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Silodosin
ATC Codes
G04CA04 — Silodosin
AHFS Codes
  • 12:16.04.12 — Selective Alfa-1-adrenergic Blocking Agents
FDA label
Download (846 KB)
MSDS
Download (479 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAbacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentNocturia / Prostatic Hyperplasia1
2CompletedTreatmentRenal Stones / Ureteral Calculus / Urolithiasis1
2CompletedTreatmentUrinary Tract Stones1
2RecruitingTreatmentPremature Ejaculation1
3CompletedTreatmentBenign Prostatic Hyperplasia (BPH)4
3RecruitingSupportive CareProstate Cancer / Urinary Problems1
3TerminatedTreatmentExpulsive Medical Therapy / Renal Stones1
3WithdrawnTreatmentRenal Stones1
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH)2
4CompletedTreatmentBenign Prostatic Hyperplasia (BPH) / Nocturia1
4CompletedTreatmentBenign Prostatic Hypertrophy (BPH)1
4CompletedTreatmentNeurogenic Bladder Dysfunction / Voiding Dysfunction1
4CompletedTreatmentUreteral Stones1
4TerminatedTreatmentUreteral Calculus / Ureteral Stones / Ureterolithiasis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral4 mg/1
CapsuleOral8 mg/1
CapsuleOral4 mg
CapsuleOral8 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5403847No1992-11-132012-11-13Us
US5387603No1998-12-012018-12-01Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)105 - 109°CFDA label
water solubilityVery slightly soluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0111 mg/mLALOGPS
logP2.96ALOGPS
logP3.05ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)14.87ChemAxon
pKa (Strongest Basic)9.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area97.05 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity128.92 m3·mol-1ChemAxon
Polarizability49.89 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.7383
Caco-2 permeable-0.5847
P-glycoprotein substrateSubstrate0.8467
P-glycoprotein inhibitor INon-inhibitor0.5833
P-glycoprotein inhibitor IIInhibitor0.7864
Renal organic cation transporterNon-inhibitor0.7288
CYP450 2C9 substrateNon-substrate0.8226
CYP450 2D6 substrateNon-substrate0.6362
CYP450 3A4 substrateSubstrate0.6585
CYP450 1A2 substrateNon-inhibitor0.7439
CYP450 2C9 inhibitorNon-inhibitor0.7569
CYP450 2D6 inhibitorNon-inhibitor0.5958
CYP450 2C19 inhibitorNon-inhibitor0.5562
CYP450 3A4 inhibitorInhibitor0.7424
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5723
Ames testNon AMES toxic0.6667
CarcinogenicityNon-carcinogens0.8529
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4845 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.98
hERG inhibition (predictor II)Inhibitor0.8366
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0121090000-11833eeb1f3c76d92dda
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01ot-1490800000-2175bd3c7bc607b74fee
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000x-1980000000-5d01eb798b6009518223

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolecarboxylic acids and derivatives
Direct Parent
Indolecarboxamides and derivatives
Alternative Parents
Dialkylarylamines / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Aralkylamines / Vinylogous amides / 1,3-aminoalcohols / Amino acids and derivatives / Primary carboxylic acid amides / Dialkylamines
show 7 more
Substituents
Indolecarboxamide derivative / Phenoxy compound / Phenol ether / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Alkyl aryl ether / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Vinylogous amide
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089]
  2. Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr: Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10. doi: 10.1345/aph.1M320. Epub 2010 Jan 13. [PubMed:20071497]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion. Functions as a floppase that translocates specifically phosphatidylcholine (PC) from ...
Gene Name
ABCB4
Uniprot ID
P21439
Uniprot Name
Phosphatidylcholine translocator ABCB4
Molecular Weight
141521.845 Da
References
  1. Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089]

Drug created on March 19, 2008 10:17 / Updated on February 21, 2018 17:22